<p>Scilex（纳斯达克代码：SCLX - 获取免费报告）于周五发布了季度财报。该公司报告每股收益（EPS）为（$22.17），低于市场共识预期的（$0.41），差距为（$21.76），据 Zacks 报道。</p>
<h2>Scilex 价格表现</h2>
<ul>
<li>Datavault AI 的 314% 上涨：巨大的潜力还是华尔街的幻影？</li>
</ul>
<p>周五中午交易时，SCLX 的股价下跌了$0.18，跌至$17.69。该公司的股票交易量为 61,732 股，而其平均交易量为 146,317 股。该公司的 50 日移动平均价格为$19.97，200 日移动平均价格为$13.12。Scilex 的 52 周低点为$3.60，52 周高点为$34.27。该股票的市值为 1.3427 亿美元，市盈率为-1.11，贝塔值为 1.34。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者最近调整了对该股票的持有。高盛集团在第一季度将其在 Scilex 的持股增加了 31.2%。高盛集团现在拥有 136,352 股该公司的股票，价值$34,000，此前在上个季度增持了 32,449 股。挪威银行在第二季度收购了 Scilex 的新股份，价值$80,000。最后，法国巴黎银行金融市场在第三季度将其在 Scilex 的持股增加了 189.6%。法国巴黎银行金融市场现在拥有 7,430 股该公司的股票，价值$146,000，此前在上个季度增持了 4,864 股。机构投资者持有该公司 69.67% 的股份。</p>
<h2>分析师评级调整</h2>
<ul>
<li>Datavault AI：由大额资金支持的新 AI 竞争者</li>
</ul>
<p>另外，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Scilex 的 “卖出（d-）” 评级。两位分析师对该股票给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “减持”，平均目标价格为$630.00。</p>
<p><strong>查看我们最新的 SCLX 股票分析</strong></p>
<h2>关于 Scilex</h2>
<p>（获取免费报告）</p>
<p>Scilex 控股公司专注于收购、开发和商业化非阿片类疼痛管理产品，以治疗急性和慢性疼痛。其商业产品包括 ZTlido（利多卡因外用系统）1.8%（ZTlido），一种用于缓解与带状疱疹后神经痛（PHN）相关的神经性疼痛的处方利多卡因外用产品；ELXYB，一种用于急性治疗成人偏头痛（有或没有先兆）的即用口服溶液；以及 GLOPERBA，一种用于预防成人痛风发作的液体口服版本的抗痛风药物秋水仙碱。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票比 Scilex 更好</li>
<li>如何计算股票利润</li>
<li>这三家被低估的科技巨头准备反弹吗？</li>
<li>百分比涨幅告诉投资者什么，以及为什么它们并不能告诉全部故事</li>
<li>如果你等着抄底，美光科技可能会让你错过</li>
<li>现在买入 P&amp;G，在它创下新高之前</li>
<li>三只悄然推动 AI 和科技革命的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0NMWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0NMWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Scilex 吗？</h2>
<p>在考虑 Scilex 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Scilex 并不在名单上。</p>
<p>虽然 Scilex 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SCLX

<p>Scilex（纳斯达克代码：SCLX）报告的季度每股收益（EPS）为（$22.17），显著低于市场共识预期的（$0.41），差距达到$21.76。该公司的股票交易价格下跌至$17.69，市值为 1.3427 亿美元。机构投资者持有该公司 69.67% 的股份。分析师对 Scilex 给予了 “减持” 评级，目标股价为$630.00。Scilex 专注于非阿片类疼痛管理产品，包括 ZTlido、ELYXYB 和 GLOPERBA</p>

<p>Scilex (NASDAQ:SCLX - Get Free Report) posted its quarterly earnings data on Friday. The company reported ($22.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($21.76), Zacks reports.</p>
<div class="lb-trans"><p>Scilex（纳斯达克代码：SCLX - 获取免费报告）于周五发布了季度财报。该公司报告每股收益（EPS）为（$22.17），低于市场共识预期的（$0.41），差距为（$21.76），据 Zacks 报道。</p>
</div><h2>Scilex Price Performance</h2>
<div class="lb-trans"><h2>Scilex 价格表现</h2>
</div><ul>
<li>Datavault AI's 314% Upside: Huge Potential or Wall Street Mirage?</li>
</ul>
<div class="lb-trans"><ul>
<li>Datavault AI 的 314% 上涨：巨大的潜力还是华尔街的幻影？</li>
</ul>
</div><p>Shares of SCLX traded down $0.18 during mid-day trading on Friday, hitting $17.69. The company's stock had a trading volume of 61,732 shares, compared to its average volume of 146,317. The firm has a 50-day moving average price of $19.97 and a 200 day moving average price of $13.12. Scilex has a fifty-two week low of $3.60 and a fifty-two week high of $34.27. The stock has a market capitalization of $134.27 million, a price-to-earnings ratio of -1.11 and a beta of 1.34.</p>
<div class="lb-trans"><p>周五中午交易时，SCLX 的股价下跌了$0.18，跌至$17.69。该公司的股票交易量为 61,732 股，而其平均交易量为 146,317 股。该公司的 50 日移动平均价格为$19.97，200 日移动平均价格为$13.12。Scilex 的 52 周低点为$3.60，52 周高点为$34.27。该股票的市值为 1.3427 亿美元，市盈率为-1.11，贝塔值为 1.34。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. lifted its position in shares of Scilex by 31.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 136,352 shares of the company's stock valued at $34,000 after acquiring an additional 32,449 shares during the last quarter. Norges Bank acquired a new stake in shares of Scilex during the second quarter worth $80,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Scilex by 189.6% during the third quarter. BNP Paribas Financial Markets now owns 7,430 shares of the company's stock valued at $146,000 after purchasing an additional 4,864 shares during the last quarter. Institutional investors own 69.67% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近调整了对该股票的持有。高盛集团在第一季度将其在 Scilex 的持股增加了 31.2%。高盛集团现在拥有 136,352 股该公司的股票，价值$34,000，此前在上个季度增持了 32,449 股。挪威银行在第二季度收购了 Scilex 的新股份，价值$80,000。最后，法国巴黎银行金融市场在第三季度将其在 Scilex 的持股增加了 189.6%。法国巴黎银行金融市场现在拥有 7,430 股该公司的股票，价值$146,000，此前在上个季度增持了 4,864 股。机构投资者持有该公司 69.67% 的股份。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><ul>
<li>Datavault AI: The New AI Contender Backed by Big Funding</li>
</ul>
<div class="lb-trans"><ul>
<li>Datavault AI：由大额资金支持的新 AI 竞争者</li>
</ul>
</div><p>Separately, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Scilex in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of &#34;Reduce&#34; and an average price target of $630.00.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Scilex 的 “卖出（d-）” 评级。两位分析师对该股票给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “减持”，平均目标价格为$630.00。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on SCLX</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 SCLX 股票分析</strong></p>
</div><h2>About Scilex</h2>
<div class="lb-trans"><h2>关于 Scilex</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.</p>
<div class="lb-trans"><p>Scilex 控股公司专注于收购、开发和商业化非阿片类疼痛管理产品，以治疗急性和慢性疼痛。其商业产品包括 ZTlido（利多卡因外用系统）1.8%（ZTlido），一种用于缓解与带状疱疹后神经痛（PHN）相关的神经性疼痛的处方利多卡因外用产品；ELXYB，一种用于急性治疗成人偏头痛（有或没有先兆）的即用口服溶液；以及 GLOPERBA，一种用于预防成人痛风发作的液体口服版本的抗痛风药物秋水仙碱。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Scilex</li>
<li>How to Calculate Stock Profit</li>
<li>Are These 3 Oversold Tech Giants Ready to Rebound?</li>
<li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li>
<li>If You Wait for the Dip, Micron Technology Could Leave You Behind</li>
<li>Buy P&amp;G Now, Before It Sets A New All-Time High</li>
<li>3 Stocks Quietly Powering the AI and Tech Revolution</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Scilex 更好</li>
<li>如何计算股票利润</li>
<li>这三家被低估的科技巨头准备反弹吗？</li>
<li>百分比涨幅告诉投资者什么，以及为什么它们并不能告诉全部故事</li>
<li>如果你等着抄底，美光科技可能会让你错过</li>
<li>现在买入 P&amp;G，在它创下新高之前</li>
<li>三只悄然推动 AI 和科技革命的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0NMWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=SCLX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Scilex Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Scilex 吗？</h2>
</div><p>Before you consider Scilex, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Scilex 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scilex wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Scilex 并不在名单上。</p>
</div><p>While Scilex currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Scilex 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Scilex（纳斯达克代码：SCLX）公布了收益结果，每股收益比预期低 21.76 美元